שולי רווח נקי ממכירות Seelos Therapeutics (SEEL)

Seelos Therapeutics, Inc - לוגו גרפי של המנפיק SEEL

Seelos Therapeutics is facing a liquidity shortage and the depletion of reserves due to a lack of sales. However, Seelos Therapeutics attracts leading neurobiologists through a flexible culture and stock options to develop depression treatments. Net profit margins on shipments confirm these challenges, where 0.00 determines the current status of the parameter. Meanwhile, risks of failed ketamine drug trials and a dependence on external financing persist.

שולי רווח נקי Seelos Therapeutics (SEEL): לתקופה 04.07.2022 - 26.10.2024

פילוחי נתונים אנליטיים מרוכזים עבור Seelos Therapeutics (SEEL)

- שער מניה ותחזית מחירי מומחים:
אנליטיקה מסכמת של החברה:Seelos Therapeutics, SEEL
מוצר המיוצר על ידי Seelos Therapeutics Inc

The asset's fundamental risks are determined by the business's ability to generate profit per unit of revenue. For Seelos Therapeutics (SEEL), a key efficiency factor is the delegation of drug trials to external CRO partners. By analyzing the net profit margin trend, an investor assesses the share of net income after deducting all operating expenses. This indicator measures margin resilience against inflation and market conditions. A contraction of this metric may signal a rise in hidden outsourcing costs.